secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beta Bionics, Inc. (BBNX)
CIK:        0001674632
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001171843-26-002614
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beta Bionics Q1 net sales up 57% YoY to $27.6M; raises FY 2026 guidance
-----------------------------------------------------------------------

- Net sales $27.6M (+57% YoY); PBP channel $10.7M (+181% YoY).
- Gross margin 59.5% (+864 bps); loss from ops $24.3M (-88% of sales vs -106%).
- Net loss $21.9M vs $28.7M YoY; adjusted EBITDA -$17.7M (-64% vs -88% of sales).
- Cash and investments $239.5M; raised full year 2026 guidance (quantified details not provided).
- New patient starts declined 10-20% sequentially; 70% from MDI users.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674632/000117184326002614/0001171843-26-002614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674632/000117184326002614/f8k_042126.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-002614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer